Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.16%
#3 Velvet Velvet +44.46%
#4 Akedo Akedo +40.57%
#5 Black Phoenix Black Phoenix +33.98%
#6 Cross Cross +24.15%
#7 Cap Cap +20.35%
#8 DoubleZero DoubleZero +14.60%
#9 Tutorial Tutorial +11.59%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.77%
Coin of the day
Islamic Coin Islamic Coin
設定
言語
日本
通貨
USD
テーマ
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
株式のランク #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
株価
$0.11725176
最終同期: 2025-07-14
時価総額
$481.50K
変化（1日）
-0.20%
変化（1年）
0.00%
国
FR
取引 PHAXIAM Therapeutics S.A. (PHXM)

カテゴリー

Healthcare
PHAXIAM Therapeutics S.A.（PHXM）の利益
Jun 2024 時点の利益 TTM: $-23.51M
PHAXIAM Therapeutics S.A. の最新の財務報告によると、同社の現在の利益は $-23.51M です。2022 年には $-1.28M の利益を上げ、これは 2021 年の利益 $-65.34M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
PHAXIAM Therapeutics S.A. の利益の推移（2016 〜 2026）
各年末の利益
年 利益 変化
2026 (TTM) $-23.51M -14.00%
2023 $-27.34M 2,036.64%
2022 $-1.28M -98.04%
2021 $-65.34M -30.07%
2020 $-93.44M 25.10%
2019 $-74.70M 52.60%
2018 $-48.95M 11.10%
2017 $-44.06M 64.85%
2016 $-26.73M 0.00%
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -22,533.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -8,395.72%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -12,882.70%
BE